MiR-29b inhibits the growth of glioma via MYCN dependent way

Guan Sun; Jingmin Lu; Chuang Zhang; Ran You; Lei Shi; Nan Jiang; Dekang Nie; Jian Zhu; Min Li; Jun Guo

doi:10.18632/oncotarget.16780

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MiR-29b inhibits the growth of glioma via MYCN dependent way

Guan Sun, Jingmin Lu, Chuang Zhang, Ran You, Lei Shi, Nan Jiang, Dekang Nie, Jian Zhu, Min Li and Jun Guo _

PDF | HTML | How to cite

Oncotarget. 2017; 8:45224-45233. https://doi.org/10.18632/oncotarget.16780

Metrics: PDF 1696 views | HTML 2176 views | ?

Abstract

Guan Sun1,*, Jingmin Lu2,*, Chuang Zhang3,*, Ran You4, Lei Shi5, Nan Jiang1, Dekang Nie1, Jian Zhu1, Min Li6 and Jun Guo1

1Department of Neurosurgery, First People’s Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng 224001, PR China

2Department of Neurology, The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, Huai’an 223001, PR China

3Department of Medical Oncology, The 81st Hospital of People's Liberation Army, Nanjing 210002, PR China

4Department of Interventional Radiology, Nantong University Affiliated Hospital, Nantong 226000, PR China

5Department of Neurosurgery, The First People's Hospital of Kunshan Affiliated with Jiangsu University, Suzhou 215300, PR China

6Department of Neurosurgery, Jiangning Hospital Affiliated with Nanjing Medical University, Nanjing 211100, PR China

*These authors contributed equally to this work

Correspondence to:

Jun Guo, email: [email protected]

Min Li, email: [email protected]

Keywords: glioma, miR-29b, MYCN

Received: March 08, 2017 Accepted: March 24, 2017 Published: April 01, 2017

ABSTRACT

MiR-29b is widely involved in diverse cancers. We plan to study its role in glioma. The expression of miR-29b was detected by real-time polymerase chain reaction (PCR) and we found the expression of miR-29b was decreased in glioma. Cell proliferation was evaluated by cell counting kit (CCK8) and 5-Ethynyl-2’- deoxyuridine (EdU) and cell apoptosis was assayed with flow cytometry assay (FCA), which indicated miR-29b can inhibit the proliferation and promote the apoptosis of glioma cells. The target of miR-29b was predicted using miRanda, TargetScan and PicTar sofeware and we also found MYCN was a direct target of miR-29b in glioma cells and miR-29b inhibited the proliferation of glioma cells via MYCN dependent way. Subcutaneous xenotransplantation model was designed to investigate the affection of miR-29b on glioma growth. The effectiveness of miR-29b for glioma prediction was also performed and we determined miR-29b can stably exist and may act as a biomarker for the diagnosis of glioma. As a conclusion, miR-29b inhibits the growth of glioma via MYCN dependent way and can be a biomarker for the diagnosis of glioma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16780

Publication Alerts

Research Papers:

MiR-29b inhibits the growth of glioma via MYCN dependent way

Abstract